Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

—Data from this real-world study revealed that patients with MS being treated with DMTs had a disproportionally higher number of cases of herpes zoster compared with patients treated with other ...

Multiple sclerosis, often called MS, is a long-lasting disease that affects the brain and spinal cord. It happens when the ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

Dr. Parisa Khosravi knows exactly what her patients are going through and the shock they might experience when she delivers the diagnosis. As a neuroimmunologist at Central Texas Neurology Consultants ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis have won ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

Annual out-of-pocket treatment costs for multiple sclerosis increased by 125% from 2002 to 2021 in the US, driven mainly by ...

Tiziana Life Sciences ( ($TLSA) ) just unveiled an update. On December 29, 2025, Tiziana Life Sciences reported that it has filed its seventh ...